Your heart contracts and relaxes roughly 100,000 times a day. Each cycle depends on a molecular off-switch: a protein called tropomyosin¹¹ tropomyosin
Tropomyosin is a long, rod-shaped protein that wraps around actin filaments in muscle cells. At rest it physically blocks the sites where myosin (the motor protein) can grab actin, preventing contraction until calcium signals it to step aside that sits like a lid on actin filaments, blocking the cardiac motor machinery until calcium says "go." The TPM1 E180G variant — a single amino-acid substitution replacing glutamic acid with glycine at position 180 of cardiac alpha-tropomyosin — weakens that lid. The result is a heart that can't fully disengage its own throttle, pushing toward hypertrophic cardiomyopathy (HCM): progressive thickening of the left ventricular wall that stiffens the pump and, in some carriers, triggers dangerous arrhythmias.

E180G was first identified in the landmark 1994 Cell paper by Thierfelder and colleagues²² landmark 1994 Cell paper by Thierfelder and colleagues
Thierfelder L et al., Cell 77:701–712, 1994 — the paper that established familial HCM as "a disease of the sarcomere" by showing mutations in multiple distinct sarcomeric proteins produce the same cardiac phenotype, which catalogued the first alpha-tropomyosin mutations causing familial HCM on chromosome 15q2. It is classified as ClinVar Pathogenic (VCV000012455), supported by multiple independent submitters without conflicts, and listed as the first allelic variant in OMIM entry 191010.

The Mechanism

Normally, tropomyosin exists in a tightly coiled double-helix that shifts between three positions — blocked, closed, and open — depending on calcium levels. The Glu180Gly substitution removes a charged glutamic acid residue and replaces it with tiny glycine, which has almost no side chain. This dramatically increases the local and global flexibility³³ local and global flexibility
Measured as persistence length — a quantitative index of a polymer's resistance to bending. Wild-type tropomyosin has a persistence length of approximately 150 nm; E180G reduces this, making the filament more prone to curving and bending of the tropomyosin filament by approximately 35% compared to wild-type protein.

The consequence is mechanical: excess flexibility impedes normal propagation of the "blocked → open" activation signal along the thin filament, and requires a smaller calcium signal to trigger contraction. Atomic force microscopy⁴⁴ Atomic force microscopy
A technique that traces the physical contour of a single protein molecule along a surface, allowing direct measurement of bending at nanometer scale and molecular dynamics simulations⁵⁵ molecular dynamics simulations
Computer models that simulate how individual atoms in a protein move over time, revealing conformational changes too fast to observe experimentally both confirm this increased flexibility, which destabilizes the low-calcium "off" state of cardiac muscle. The result: higher resting actin-myosin interaction, enhanced contractility, and — critically — failure of the muscle to fully relax between beats (diastolic dysfunction).

The Evidence

The molecular evidence for E180G's pathogenic mechanism is strong and consistent across independent methods:

Structural mechanics: Li et al., 2012⁶⁶ Li et al., 2012
Li XE et al. Biochem Biophys Res Commun 2012 — examined both D175N and E180G using electron microscopy of isolated tropomyosin molecules; persistence length reductions were statistically significant across >200 molecules per condition showed increased bending flexibility leads to excess Ca²⁺-activation and shifts regulatory equilibrium toward the "on" state even at diastolic calcium concentrations.

Calcium sensitivity and kinetics: Sewanan et al., 2016⁷⁷ Sewanan et al., 2016
Sewanan LR et al. Front Physiol 2016 — computational myofilament model incorporating E180G-specific stiffness and duty-cycle changes; validated against published in vitro motility data predicted E180G increases both maximum and diastolic force generation, and slows the time from peak tension to 50% relaxation — a signature of HCM diastolic dysfunction.

Signaling cascades: Robinson et al., 2018⁸⁸ Robinson et al., 2018
Robinson P et al. J Biol Chem 2018 — guinea pig cardiomyocyte model expressing thin-filament HCM mutations including the closely related D175N demonstrated that increased myofilament calcium buffering from these mutations elevates diastolic calcium and activates CaMKII and calcineurin/NFAT⁹⁹ CaMKII and calcineurin/NFAT
Two calcium-sensitive kinases that, when chronically activated, trigger gene programs causing hypertrophy, fibrosis, and arrhythmia — the cardinal features of HCM signaling cascades — providing a mechanism linking the sarcomeric defect to macroscopic cardiac remodeling.

Actin-myosin interaction: Kopylova et al., 2019¹⁰¹⁰ Kopylova et al., 2019
Kopylova GV et al. J Muscle Res Cell Motil 2019 — combined single-molecule optical trap and ensemble in vitro motility assay; both HCM mutations E180G and D175N increased calcium sensitivity in ensemble measurements, whereas dilated cardiomyopathy mutations showed opposite effects confirmed E180G increases thin-filament sliding velocity and calcium sensitivity in reconstituted assays, in the same direction as D175N — and in the opposite direction from dilated cardiomyopathy TPM1 mutations, validating the disease-specific mechanism.

E180G is ultra-rare globally (absent from gnomAD population databases), consistent with its being a disease-causing variant with strong negative selection pressure. The variant is classified Pathogenic with a 3-star ClinVar review status reflecting consistent classification across multiple independent submitters.

Practical Actions

Identifying an E180G carrier changes clinical management in ways that directly reduce morbidity and mortality. HCM is one of the most common causes of sudden cardiac death in individuals under 35. For carriers, the priorities are: (1) confirm diagnosis and baseline LV morphology, (2) identify high-risk features that warrant ICD implantation or septal reduction therapy, and (3) extend family testing to first-degree relatives. The autosomal dominant inheritance means each biological child of a carrier has a 50% chance of inheriting the variant.

Avoidance of competitive athletics and extreme exertion is recommended pending full clinical evaluation — sudden cardiac death events in HCM are disproportionately exercise-associated.

Interactions

E180G's closely related neighbor on chromosome 15, TPM1 D175N (rs104894503), shares nearly identical functional properties: both increase tropomyosin flexibility and calcium sensitivity, both were identified in the same 1994 paper, and both are classified Pathogenic for HCM. D175N is a Finnish founder mutation (accounting for 6.5% of Finnish HCM cases in a cohort of 306 patients) but is not known to interact with E180G as a compound heterozygote — these are independent dominant mutations in the same gene affecting adjacent codons.

Other sarcomeric protein HCM genes — MYBPC3 (rs36211723), MYH7, TNNT2 — can produce overlapping clinical phenotypes. Patients with multiple sarcomeric variants ("double positive" HCM) tend to have more severe hypertrophy and earlier onset, though compound heterozygosity specifically for E180G has not been studied in published literature.

The NOD2 gene encodes a cytosolic pattern recognition receptor¹¹ pattern recognition receptor
NOD2 senses muramyl dipeptide (MDP), a fragment of bacterial cell-wall peptidoglycan that detects bacterial cell-wall fragments and mounts an immune defense in the intestinal lining. It was the first gene identified for Crohn's disease²² the first gene identified for Crohn's disease
NOD2 was discovered as a susceptibility locus in the IBD1 linkage region on chromosome 16q12 susceptibility and remains the most studied single gene in inflammatory bowel disease genetics. The rs104895444 variant changes valine to methionine at protein position 793 (Val793Met), a site within the leucine-rich repeat domain that participates in bacterial ligand sensing.

The Mechanism

NOD2 protein consists of two N-terminal CARD (caspase-recruitment) domains³³ CARD (caspase-recruitment) domains
CARDs mediate protein-protein interactions that activate the NF-κB signaling cascade, a central NOD domain, and C-terminal leucine-rich repeats (LRRs). The LRR domain directly recognizes muramyl dipeptide (MDP), the minimal bioactive peptidoglycan fragment from both Gram-positive and Gram-negative bacteria. Successful MDP binding triggers NOD2 oligomerization, RIPK2 recruitment, and downstream NF-κB activation⁴⁴ NF-κB activation
NF-κB activates genes encoding antimicrobial peptides (defensins), pro-inflammatory cytokines, and barrier-strengthening proteins — a coordinated response that clears bacteria while reinforcing the epithelial barrier.

The Val793Met change lies within the LRR domain at a position conserved across mammals. While ClinVar currently classifies this variant as likely benign based on existing submissions, it was identified in deep resequencing⁵⁵ identified in deep resequencing
Rivas et al. 2011 whole-exome resequencing of 16,054 CD and 12,153 UC cases identified V793M among additional rare NOD2 risk variants beyond the three classic mutations as one of several rare NOD2 missense variants independently associated with IBD in a genome-wide study of over 45,000 individuals. The substitution of valine (a small non-polar amino acid) for methionine (a larger sulfur-containing amino acid) could alter LRR domain folding or MDP-binding geometry, potentially reducing the sensitivity of bacterial sensing.

The Evidence

The genetic case for Val793Met rests on its identification in a landmark deep-resequencing study⁶⁶ landmark deep-resequencing study
Rivas et al. sequenced 163 genes in 9 GWAS loci in 16,054 CD cases, 12,153 UC cases, and 17,575 controls, identifying V793M among four additional independent NOD2 risk factors that interrogated over 45,000 IBD cases and controls. The study identified Val793Met (V793M) as one of four additional independent NOD2 risk factors beyond the three classic variants (R702W, G908R, L1007fs), each of which carries odds ratios of 2–4 for heterozygotes and 17–40 for compound heterozygotes or homozygotes.

The broader NOD2-Crohn's connection is established beyond any doubt⁷⁷ established beyond any doubt
More than 145 published studies confirm NOD2 as the strongest non-HLA locus for Crohn's disease. The three classic variants together account for ~80% of NOD2-attributable CD risk in European populations; 27 rare mutations account for the remaining ~20%⁸⁸ 27 rare mutations account for the remaining ~20%
Lesage et al. 2002 found that in 612 IBD patients, the three major variants contributed 81% of disease-associated alleles while 27 rare variants contributed 19%. Val793Met occupies this second tier — rare individually, but clinically meaningful in the context of compound heterozygosity.

The evidence for Val793Met as a standalone risk factor is moderate rather than established: it is supported by one large resequencing study but lacks the replication depth of the three major NOD2 variants. Its individual contribution to Crohn's disease risk is likely modest. The variant's significance is amplified when a second NOD2 hit is present on the opposite chromosome.

Practical Implications

Carriers of one copy of the A allele face a mildly elevated risk for Crohn's disease, primarily through two mechanisms: direct LRR domain disruption and, more importantly, the possibility of compound heterozygosity with another NOD2 variant. Because Val793Met is rare (~0.2% allele frequency in Europeans), most carriers will not have a second NOD2 hit — but those who do face substantially elevated risk.

NOD2-associated Crohn's disease has a characteristic phenotype: ileal or ileocolonic location, fibrostenotic (stricturing) complications, and a tendency toward surgical resection. Patients with two NOD2 mutations⁹⁹ Patients with two NOD2 mutations
Double-dose NOD2 carriers show earlier onset, 53% stricturing rate vs 28%, and more frequent ileal-only disease show earlier disease onset, more stricturing behavior, and higher surgical rates than single-copy carriers or non-carriers.

NOD2 variants are also being used as biomarkers to guide therapy¹⁰¹⁰ biomarkers to guide therapy
NOD2 genotype informs risk of steroid refractoriness, surgical necessity, and consideration of early biologic use decisions in Crohn's disease management. Carriers with established IBD may benefit from early specialist involvement to monitor for fibrostenotic complications.

Interactions

The clinical significance of Val793Met is substantially magnified by compound heterozygosity. When this variant occurs on one chromosome alongside a different NOD2 variant — such as R702W (rs2066844), G908R (rs2066845), or L1007fs (rs2066847) — on the opposite chromosome, both alleles carry impaired function and the net NOD2 activity is severely reduced. Compound heterozygosity for two NOD2 mutations¹¹¹¹ Compound heterozygosity for two NOD2 mutations
In the large NOD2 genotype-phenotype study, double-mutation carriers showed OR ~40 for CD compared to OR ~3-4 for single-copy carriers dramatically amplifies Crohn's disease risk compared to either mutation alone.

The rs104895431 variant in the same batch belongs to the same NOD2 compound heterozygosity risk cluster. Individuals carrying both rs104895444 and rs104895431 on opposite chromosomes would have effectively zero functional NOD2 alleles, creating a high-risk state for Crohn's disease with the ileal-stricturing phenotype typical of double-NOD2-mutation carriers. This interaction is the central clinical significance of both variants — individually rare and modest, combined potentially severe.

NOD2 genotype also interacts with smoking status: NOD2 mutation carriers who smoke¹²¹² NOD2 mutation carriers who smoke
Kuenzig et al. 2017 found NOD2-smoking interaction modified stricturing phenotype risk in CD show modified disease outcomes, with smoking amplifying the stricturing tendency already present with NOD2 variants. The pathobiological pathway converges on the gut microbiome — NOD2-deficient mice develop dysbiosis and intestinal inflammation that mirrors CD, confirming the bacterial-sensing deficit hypothesis¹³¹³ confirming the bacterial-sensing deficit hypothesis
NOD2-knockout mouse models develop altered gut microbiome composition and show heightened intestinal inflammation.

Every cell in your body runs a continuous protein quality-control operation called the ubiquitin-proteasome system (UPS)¹¹ ubiquitin-proteasome system (UPS)
The UPS tags damaged or misfolded proteins with ubiquitin chains and feeds them to the proteasome — a barrel-shaped multi-subunit protease — for destruction. It also controls the half-lives of regulatory proteins, including the inhibitors of inflammatory signalling. The 20S core proteasome is assembled from alpha and beta subunits; PSMA6 encodes the alpha-6 subunit, which forms part of the outer rings that gate substrate entry. The rs1048990 variant sits just eight bases upstream of the translation start in the 5'UTR of PSMA6 exon 1 — a location that has a quiet but measurable effect on how much PSMA6 protein the cell produces.

The G allele enhances PSMA6 transcription²² enhances PSMA6 transcription
Demonstrated by reporter assays and confirmed by the correlation between genotype and mRNA expression levels across multiple population cohorts. More PSMA6 means more assembled proteasomes, and more proteasome activity accelerates the degradation of IκB — the inhibitor of NF-κB³³ IκB — the inhibitor of NF-κB
IκB normally sequesters NF-κB in the cytoplasm, preventing it from driving expression of inflammatory cytokines (TNF-α, IL-1β, IL-6). When IκB is phosphorylated after an immune stimulus, it is tagged for proteasomal degradation. More proteasomes degrade phospho-IκB faster, releasing NF-κB to the nucleus more readily. The result is a lower threshold for inflammatory gene expression — not a dramatic immune deficiency, but a subtle amplification of the inflammatory signal across the lifetime.

The Mechanism

The -8C>G substitution does not change any protein but alters the regulatory architecture of the PSMA6 5'UTR. Functional studies demonstrated that PSMA6 knockdown using siRNA reduced NF-κB activation by stabilising phosphorylated IκB in cultured cells⁴⁴ Functional studies demonstrated that PSMA6 knockdown using siRNA reduced NF-κB activation by stabilising phosphorylated IκB in cultured cells
The experiment directly connects proteasome abundance to NF-κB activity: less proteasome → slower IκB degradation → more IκB retained → less NF-κB in the nucleus → less inflammatory gene expression. Conversely, the G allele's enhanced transcription runs this pathway in the opposite direction — faster IκB turnover, lower threshold for NF-κB activation, and greater cytokine output in response to inflammatory stimuli.

This mechanism is relevant across multiple disease contexts: chronic low-grade inflammation drives atherosclerosis and plaque instability in cardiovascular disease, and overactive NF-κB signalling is a central feature of autoimmune conditions including rheumatoid arthritis, SLE, and psoriasis.

The Evidence

The original discovery study⁵⁵ The original discovery study
Ozaki K et al. A functional SNP in PSMA6 confers risk of myocardial infarction in the Japanese population. Nat Genet. 2006 found the G allele in 2,592 MI cases and 2,851 controls from Japan, with striking significance (chi²=21.1, p=4.4×10⁻⁶) and a minor allele frequency of ~0.35 in this population — much higher than in Europeans (~0.17). Replication was confirmed in an independent Japanese cohort.

A meta-analysis pooling 15,991 cases and 16,784 controls⁶⁶ meta-analysis pooling 15,991 cases and 16,784 controls
Wang M et al. Quantitative assessment of the influence of PSMA6 variant (rs1048990) on coronary artery disease risk. Mol Biol Rep. 2013 found a per-G-allele OR of 1.09 (95% CI 1.02–1.16, p=0.006) globally, with the GG homozygous recessive model yielding OR 1.38 (1.22–1.57). The effect was significant in East Asians but did not reach significance in Europeans when analysed separately — likely because GG homozygotes are far rarer in European populations (~2% vs ~9% in Japanese), reducing statistical power.

A UK replication study in 6,946 MI cases and 2,720 controls⁷⁷ A UK replication study in 6,946 MI cases and 2,720 controls
Balmforth AJ et al. The exon 1-8C/G SNP in the PSMA6 gene contributes only a small amount to the burden of myocardial infarction. Atherosclerosis. 2008 confirmed the GG homozygote frequency is far lower in Europeans (2.1% vs 8.9% in Japanese) and that the individual-study result was non-significant, but the combined meta-analysis consistently returned OR ~1.15 per G allele and OR ~1.38 for GG in the recessive model.

Beyond cardiovascular disease, rs1048990 has been associated with type 1 diabetes⁸⁸ type 1 diabetes
OR 2.04, 95% CI 1.38–3.03, p<0.001 in a Latvian cohort, with expression correlates across 14 UPS-related genes, juvenile idiopathic arthritis⁹⁹ juvenile idiopathic arthritis
Polish children study with PSMA6 rs1048990 significant for JIA specifically, and psoriasis¹⁰¹⁰ psoriasis
PSMA6 -8C>G among significant variants in Polish adult psoriasis patients. A male-specific association with asthma was also found in Lithuanian patients, consistent with sex-differential NF-κB signalling.

The breadth of associations across inflammatory and autoimmune phenotypes is expected from a variant that modulates a master inflammatory transcription factor, though the effect size at any single locus is modest (OR 1.1–1.4), fitting a complex polygenic architecture.

Practical Implications

The G allele's elevated NF-κB tone is not manageable through generic anti-inflammatory strategies (these are excluded per platform rules), but there are genotype-specific consequences worth acting on. GG homozygotes carry the highest cardiovascular inflammatory burden. CG heterozygotes carry intermediate risk. The most actionable areas are cardiovascular biomarker monitoring — since the mechanism is inflammatory plaque instability — and awareness of the autoimmune associations for early detection.

Interactions

PSMA6 encodes one of 14 alpha-subunit isoforms of the 20S proteasome. Other proteasome subunit genes have been studied alongside rs1048990: rs2277460 in PSMA6 (a second variant in the same gene), rs2295826 and rs2295827 in PSMC6 (a 19S regulatory particle ATPase), and rs2348071 in PSMA3. Haplotypes spanning PSMA6 and the neighbouring KIAA0391 gene cluster on chromosome 14q13 show stronger associations with coronary artery disease than rs1048990 alone. Individuals carrying risk alleles across multiple proteasome subunit loci may have compounded NF-κB dysregulation, though published compound heterozygosity data remain limited.

Aspirin and NSAIDs are among the best-studied cancer-prevention agents in medicine. Regular aspirin use is associated with a roughly 30% lower risk of colorectal cancer¹¹ roughly 30% lower risk of colorectal cancer
Meta-analyses consistently show OR ~0.69 for regular vs. non-regular aspirin/NSAID users across large population studies — a finding replicated across dozens of cohort and case-control studies. But this protection is not evenly distributed across people. Your genome contains switches that determine whether aspirin's cancer-fighting effect works for you.

The rs10505806 variant sits in a biologically active intergenic region on chromosome 12p12.3, approximately 726 kilobases downstream of the MGST1 gene. MGST1 encodes microsomal glutathione S-transferase 1, a MAPEG-family enzyme that synthesizes prostaglandin E2 (PGE2)²² microsomal glutathione S-transferase 1, a MAPEG-family enzyme that synthesizes prostaglandin E2 (PGE2)
MAPEG = membrane-associated proteins in eicosanoid and glutathione metabolism; PGE2 is the key prostaglandin that drives colorectal cancer cell proliferation and suppresses anti-tumor immunity. Aspirin inhibits COX-1 and COX-2 to reduce prostaglandin production — but MGST1 provides an alternative, COX-independent PGE2 synthesis route that aspirin does not directly block.

The Mechanism

The chr12p12.3 locus containing rs10505806 and the nearby rs2965667 variant appears to regulate MGST1 expression through long-range enhancer elements. When aspirin suppresses COX-derived prostaglandins, the MGST1 pathway becomes proportionally more important³³ When aspirin suppresses COX-derived prostaglandins, the MGST1 pathway becomes proportionally more important
This is a bypass mechanism — if MGST1 expression is higher, the prostaglandin-driven tumor promotion signal is harder to silence with aspirin alone. T allele carriers at rs10505806 are in the same genomic neighborhood as T/A allele carriers at rs2965667, the variant with the strongest genome-wide evidence (P = 4.6 × 10⁻⁹) for modifying aspirin-CRC protection.

PGE2 promotes colorectal cancer through multiple mechanisms: it stimulates cancer cell proliferation, suppresses cytotoxic T-cell activity, and promotes angiogenesis. The MGST1 pathway is therefore not a minor backup — it is a key determinant of whether COX inhibition by aspirin translates into actual tumor suppression.

The Evidence

Nan et al. 2015 in JAMA⁴⁴ Nan et al. 2015 in JAMA conducted a genome-wide interaction study of aspirin/NSAID use with colorectal cancer risk, combining 5 case-control and 5 cohort studies with 8,634 cancer cases and 8,553 controls. The top hit on chromosome 12 (rs2965667 at chr12:17,291,799, 44 kb from rs10505806) reached genome-wide significance (P = 4.6 × 10⁻⁹) for modifying aspirin/NSAID protection. Individuals with the common TT genotype at rs2965667 gained strong protection from aspirin (OR 0.66), while the rare TA/AA carriers (4% of the population) showed a paradoxical increase in risk with aspirin use (OR 1.89, P = .002). rs10505806 is in this same intergenic locus and likely tags the same regulatory variation.

The overall aspirin benefit is substantial: regular use was associated with OR 0.69 (95% CI 0.64–0.74) for colorectal cancer prevention in the full analysis. Drew & Chan's 2021 review⁵⁵ Drew & Chan's 2021 review and the 2022 JAMA evidence update⁶⁶ 2022 JAMA evidence update both confirm this protective association while noting that individual variation in response is likely genetic.

Practical Actions

For the ~95% of people with the common AA genotype at rs10505806, aspirin's colorectal cancer protection is expected to be robust — consistent with the overall population benefit. For T allele carriers at this locus (AT or TT), the picture is more complex: based on evidence from the neighboring rs2965667, T-carrying genotypes may not benefit from, or could even be harmed by, aspirin used specifically for colorectal cancer chemoprevention.

This does not automatically mean T carriers should avoid aspirin for cardiovascular indications — those benefits operate through different pathways (platelet TXA2 suppression) and are largely preserved. The uncertainty is specifically about the cancer prevention use case. T carriers considering aspirin for colorectal cancer chemoprevention should discuss this genetic profile with their gastroenterologist.

Interactions

The chr12p12.3 region interacts with the IL16-containing locus on chromosome 15q25.2 (rs16973225) — the second genome-wide significant aspirin-CRC interaction identified in Nan et al. 2015. Separately, aspirin's mechanism depends on COX-2 activity, so genetic variants in PTGS2 (COX-2) are relevant co-regulators. The 2024 Science Advances genome-wide interaction study (rs72833769 near TBC1D7/MTOR, and rs350047 near PTGER4) identified additional aspirin-CRC modifiers through the mTOR and PGE2 receptor pathways — functionally linked to MGST1's role in the same prostaglandin axis.

Not all depression has the same biological roots. For roughly one in four people of European ancestry who carry at least one copy of the T allele at rs10514299, a portion of that vulnerability may trace back to the MEF2C locus¹¹ MEF2C locus
Myocyte enhancer factor 2C — a transcription factor that acts as a master regulator of synapse number, neuronal survival, and activity-dependent plasticity in the developing and adult brain on chromosome 5q14.3. This variant sits within a non-coding RNA transcript (TMEM161B-DT) immediately adjacent to MEF2C, where it is thought to influence MEF2C expression levels in brain tissue. The discovery of this locus, confirmed at P = 9.99 × 10−16 in the largest depression GWAS conducted at the time, placed MEF2C at the center of the emerging genetics of mood disorders.

The Mechanism

MEF2C belongs to the MADS-box family of transcription factors and is one of the earliest-expressed MEF2 isoforms in the developing telencephalon. It plays a central role in controlling excitatory synapse number through activity-dependent synapse elimination²² activity-dependent synapse elimination
When neurons fire, calcium signaling activates calcineurin, which dephosphorylates MEF2C, switching it from a repressor to an activator of synapse-pruning genes such as Pcdh10. In this way, MEF2C acts as a negative regulator of synaptogenesis — constraining the number of excitatory connections to maintain proper excitatory/inhibitory balance.

When MEF2C function is reduced — as the T allele at rs10514299 may cause via altered regulatory element activity — excitatory synapse pruning is impaired, disrupting cortical and hippocampal circuit calibration. Mouse models with conditional Mef2c knockout in excitatory neurons show dramatically reduced network activity, anxiety-like behavior, and cognitive deficits, mirroring phenotypes relevant to depression. MEF2C also regulates neuronal differentiation, axon guidance, and activity-dependent survival — making it a broad-spectrum orchestrator of the neural circuitry that underlies mood regulation.

Pharmacologically, this pathway is relevant beyond genetics: HDAC inhibitors³³ HDAC inhibitors
Histone deacetylase inhibitors increase histone acetylation, promoting the transcription of MEF2C target genes. Valproate — used as a mood stabilizer — is a Class I/II HDAC inhibitor; part of its mood-stabilizing effect may operate through MEF2C-dependent transcription. Valproate (valproic acid) is a known Class I/II HDAC inhibitor, and some of its therapeutic effect in mood disorders may work partly through MEF2C-dependent transcriptional activation.

The Evidence

Discovery — Hyde et al. 2016. The first large-scale depression GWAS using 23andMe data⁴⁴ The first large-scale depression GWAS using 23andMe data
Hyde CL et al. Identification of 15 genetic loci associated with risk of major depression in individuals of European descent. Nature Genetics, 2016 combined data from 75,607 cases and 231,747 controls in a discovery phase, then replicated in 45,773 cases and 106,354 controls. rs10514299 reached a joint p-value of 9.99 × 10−16 — one of the most statistically robust findings in that landmark study. The locus harbored two independent significant signals (rs10514299 and rs454214), suggesting the MEF2C region contains multiple functional elements contributing to depression risk.

Validation — Howard et al. 2019. A meta-analysis of 807,553 individuals⁵⁵ A meta-analysis of 807,553 individuals
Howard DM et al. Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions. Nature Neuroscience, 2019 (246,363 cases and 561,190 controls) identified 102 independent variants and 269 genes. MEF2C appeared in 10 of the 15 most significant biological gene-sets associated with depression, including GO_EXCITATORY_SYNAPSE, GO_POSTSYNAPSE, and GO_NEURON_SPINE — reinforcing that synaptic regulation at the MEF2C locus is not incidental but central to the biology of MDD.

Functional readout — Muench et al. 2018. A neuroimaging study in alcohol-dependent patients⁶⁶ A neuroimaging study in alcohol-dependent patients
Muench C et al. The major depressive disorder GWAS-supported variant rs10514299 in TMEM161B-MEF2C predicts putamen activation during reward processing in alcohol dependence. Translational Psychiatry, 2018 demonstrated that T allele carriers (n=45 patients vs. 45 controls) showed significantly greater putamen activation during reward anticipation (p=0.014) and loss anticipation (p=0.024–0.046). The putamen is a key node in the reward circuitry; its hyperactivation in T allele carriers provides a direct functional bridge between the GWAS finding and disrupted reward processing — a hallmark of depressive episodes.

Effect size context. The odds ratio for rs10514299 is approximately 1.05 per T allele in European ancestry populations — modest for any individual but consistent, replicated, and mechanistically coherent. Depression is highly polygenic; this variant represents one of dozens of genome-wide significant contributors.

Practical Implications

Carrying T alleles at this locus does not cause depression, but it does represent a real, biologically grounded increment in susceptibility — particularly through disrupted synaptic calibration and reward circuit regulation. The actionable insight is targeted: strategies that support MEF2C-pathway resilience include interventions with documented neuroplasticity effects. Physical exercise increases MEF2C expression⁷⁷ increases MEF2C expression
Chen SX et al. demonstrated that voluntary running upregulates Mef2c mRNA in hippocampal neurons in rodent models, suggesting exercise partially restores MEF2C pathway activity in hippocampal tissue via BDNF-dependent signaling, connecting one of the most evidence-supported depression interventions to this specific locus.

If prescribed a mood stabilizer, valproate (valproic acid) is mechanistically relevant because its HDAC-inhibiting activity upregulates MEF2C target gene transcription — a convergence between pharmacology and the genetic vulnerability encoded at this locus.

Interactions

The TMEM161B-MEF2C locus contains two independent GWAS signals: rs10514299 and the companion variant rs454214 (in MEF2C-AS2, the antisense RNA adjacent to MEF2C). Individuals carrying risk alleles at both loci may experience a cumulative effect from the same pathway. The broader MEF2C biology intersects with dopamine signaling: MEF2C regulates striatal synapse development, and SNPs in dopaminergic genes (rs1800497 DRD2/ANKK1, rs4680 COMT) may compound vulnerability through overlapping reward circuitry mechanisms.

Every time your pancreas detects rising blood sugar, it doesn't release insulin directly — it releases proinsulin, a folded precursor that needs to be cut open before it becomes active. The enzyme doing that cutting is prohormone convertase 1/3 (PC1/3)¹¹ prohormone convertase 1/3 (PC1/3)
Encoded by the PCSK1 gene on chromosome 5; cleaves inactive prohormone precursors at specific paired basic amino acid sites to generate active peptide hormones, the protein encoded by PCSK1. But PC1/3 doesn't work on proinsulin alone — it also cleaves POMC into α-melanocyte-stimulating hormone (α-MSH), a key satiety signal in the brain, and proglucagon into GLP-1, the incretin that amplifies insulin release after meals. A single enzyme sits at the convergence of insulin processing, appetite regulation, and incretin signaling.

The rs10515237 variant sits within an intron of PCSK1 and is in [strong linkage disequilibrium | LD r² ≈ 0.84 in Europeans; variants that are tightly co-inherited — measuring one reliably predicts the other] with rs6234 and rs6235, the non-synonymous variants encoding the Q665E-S690T haplotype in the C-terminal domain of PC1/3. When you carry the G allele at rs10515237, you very likely also carry the functional haplotype that partially reduces PC1/3 activity. This is what makes rs10515237 clinically meaningful despite being intronic itself.

The Mechanism

The Q665E-S690T amino acid pair encoded by the rs6234-rs6235 haplotype alters the C-terminal propeptide region of PC1/3. This region acts as an intramolecular chaperone that guides proper protein folding — changes to it reduce the enzyme's catalytic efficiency without abolishing function entirely. The result is a partial loss-of-function²² partial loss-of-function
Not as severe as the rare biallelic null mutations that cause severe early-onset obesity and malabsorptive diarrhea; common heterozygous variants reduce activity modestly that propagates through three downstream pathways: slower proinsulin→insulin conversion (raising the proinsulin-to-insulin ratio), reduced POMC cleavage to α-MSH (blunting melanocortin-mediated satiety), and potentially altered proglucagon processing to GLP-1 (modifying incretin responses).

The Evidence

The founding study, Benzinou et al. 2008 (Nature Genetics)³³ Benzinou et al. 2008 (Nature Genetics)
13,659 individuals of European ancestry across 8 independent cohorts; the Q665E-S690T haplotype was the strongest association signal at p = 2.31 × 10⁻¹², established common PCSK1 variants as genuine obesity risk loci. The rs6234-rs6235 haplotype — which rs10515237 tags — conferred a 22% increased risk of obesity per risk haplotype in the original cohorts. A companion functional experiment confirmed that the N221D mutation (rs6232) significantly impaired PC1/3 catalytic activity in cell-based assays.

The largest meta-analysis to date, Nead et al. 2015 (Human Molecular Genetics)⁴⁴ Nead et al. 2015 (Human Molecular Genetics)
Up to 331,175 individuals from GWAS consortia; systematic review combining literature and custom array data from diverse ethnic backgrounds, quantified the effect more precisely: the rs6234/rs6235 haplotype carries OR = 1.07 (95% CI 1.04–1.10, p = 3.00 × 10⁻⁷) for obesity, and rs6232 carries OR = 1.15 (95% CI 1.06–1.24, p = 6.08 × 10⁻⁶). These are modest effect sizes consistent with a polygenic contribution to a complex trait. A HuGE review and meta-analysis by Stijnen et al. 2014⁵⁵ HuGE review and meta-analysis by Stijnen et al. 2014
Comprehensive systematic review of all published PCSK1 association studies; examined associations with BMI, obesity, waist circumference confirmed the associations and identified that rs6232 effects were stronger in childhood obesity than adult obesity — consistent with the enzyme's role in early growth and metabolic programming.

The metabolic consequence of reduced PC1/3 activity was directly measured by Heni et al. 2010 (BMC Medical Genetics)⁶⁶ Heni et al. 2010 (BMC Medical Genetics)
1,498 German subjects with detailed OGTT and clamp studies; rs6235 minor allele frequency 25.8%: carriers of the rs6235 risk allele had 8% higher proinsulin area-under-the-curve and elevated proinsulin-to-insulin ratio, confirming that the functional haplotype measurably impairs prohormone processing in vivo.

Practical Implications

Carriers of the G allele at rs10515237 have a modestly elevated proinsulin-to-insulin ratio — their pancreatic beta cells are secreting more precursor and less active hormone per stimulus. Over time, this can translate into reduced beta-cell efficiency and elevated long-term diabetes risk. The satiety pathway impairment compounds this: if POMC-to-α-MSH conversion is reduced, the melanocortin-4 receptor pathway fires less robustly after meals, potentially raising the threshold at which fullness signals terminate eating. This combination — less effective insulin per secretory event plus blunted satiety — is the proposed mechanism linking PCSK1 variants to excess adiposity.

From a dietary standpoint, the primary lever is glycemic load. When meals generate rapid postprandial glucose peaks, beta cells secrete larger proinsulin pulses — and in PCSK1 G-allele carriers, those pulses are converted less efficiently. Spreading glucose load across the day by choosing lower-glycemic foods reduces the secretory burden on an already less-efficient processing system. Monitoring fasting proinsulin (where available) and the standard proinsulin:insulin ratio can detect beta-cell stress before HbA1c rises.

Interactions

The rs10515237/rs6234-rs6235 haplotype interacts additively with rs6232 (the N221D missense variant) within the same gene. Individuals carrying both the rs6232 risk allele and the rs6235 haplotype have two independently acting reductions in PC1/3 activity — compound heterozygosity within PCSK1 is plausible and would confer greater proinsulin accumulation. The melanocortin pathway interaction is also relevant: variants in MC4R (rs17782313) and POMC itself further modify satiety signaling downstream of PC1/3 cleavage, creating a polygenic appetite-regulation score that several GWAS consortia have begun characterizing.

Elite endurance athletes—those competing in marathons, cycling road races, cross-country skiing, and football matches requiring sustained high-intensity output for 90+ minutes—often share a common genetic signature. Among the most significant is rs1052373 in the MYBPC3 gene, which encodes cardiac myosin-binding protein C¹¹ cardiac myosin-binding protein C
a regulatory protein that fine-tunes the force and speed of heart muscle contraction. A landmark genome-wide association study²² landmark genome-wide association study
Ahmetov et al. 2020. Meta-analysis of 1,206 elite European, Russian, and Japanese athletes found that individuals with the GG genotype were 2.2 times more likely to become elite endurance athletes compared to those with AA or AG genotypes (P = 1.43 × 10⁻⁸). Among Russian elite athletes, GG homozygotes showed significantly higher VO₂max—the gold-standard measure of aerobic capacity—than AG or AA carriers (P = 0.005).

The Mechanism

Though rs1052373 is a synonymous variant³³ synonymous variant
it doesn't change the amino acid sequence of the protein—substituting one glutamic acid codon (GAG) for another (GAA) at position 1096—it appears to influence gene expression or splicing efficiency in ways that enhance cardiac adaptation to endurance training. MYBPC3 normally acts as a molecular brake on cardiac contraction: when phosphorylated during exercise, it releases myosin heads from their "super-relaxed" state, allowing them to bind actin and generate force. The G allele may subtly modulate this regulatory balance, enabling more efficient oxygen delivery during sustained high-output performance.

MYBPC3 deficiency studies⁴⁴ MYBPC3 deficiency studies
Mamidi et al. 2022. Shows MYBPC3 loss activates NF-κB pathway, reduces inflammation, and shifts metabolism toward fatty acid oxidation have revealed that partial loss of cMyBP-C function reduces cardiac inflammation and enhances fatty acid oxidation—a more efficient fuel source during prolonged exercise. This metabolic shift may explain why GG carriers show superior endurance capacity: their hearts can sustain high cardiac output longer without depleting glycogen stores or accumulating lactate.

The Evidence

The initial discovery came from a GWAS⁵⁵ discovery came from a GWAS
Miyamoto-Mikami et al. 2020. Analyzed 476,728 SNPs in 796 European elite athletes, replicated in Russian and Japanese cohorts comparing athletes in high-aerobic sports (marathon, cycling, cross-country skiing) versus low/moderate-aerobic sports (sprinting, jumping, throwing). The rs1052373 GG genotype emerged as the strongest genome-wide significant hit. Validation in independent cohorts from Russia (n=410) and Japan (n=466) confirmed the association, with the combined meta-analysis yielding an odds ratio of 2.17 (95% CI: 1.67–2.84).

A 2023 follow-up metabolomics study⁶⁶ 2023 follow-up metabolomics study
Li et al. 2023. Metabolite profiling in 120 elite Chinese athletes linked the G allele to elevated levels of androstenediol (3β,17β) disulfate (P = 1.82 × 10⁻⁵), a testosterone precursor involved in steroid metabolism. This suggests the variant influences both cardiac contractility and hormonal pathways supporting muscle recovery and adaptation. Four metabolites—quinate, theophylline, decanoylcarnitine, and ursodeoxycholic acid—were also associated with MYBPC3 expression and endurance phenotypes, though their causal roles remain under investigation.

A 2023 comprehensive review⁷⁷ A 2023 comprehensive review
Pickering & Kiely. Listed rs1052373 G among the seven most promising genetic markers for endurance athlete status, alongside PPARGC1A rs8192678 (mitochondrial biogenesis) and AMPD1 rs17602729 (purine metabolism). Importantly, the rs1052373 association held across multiple ethnic populations, suggesting a fundamental rather than population-specific effect.

Practical Actions

If you carry one or two G alleles, you possess a genetic advantage for endurance performance. Your heart is likely more efficient at sustaining high cardiac output during prolonged exercise, and your metabolic profile may favor fat oxidation over glycogen depletion. This doesn't guarantee elite status—training, nutrition, psychology, and opportunity all matter—but it does suggest your physiology is well-suited to endurance disciplines.

Training optimization: The GG genotype responds especially well to high-intensity interval training⁸⁸ high-intensity interval training
4×4 min at 90-95% HRmax with 3 min active recovery improves VO₂max more than steady-state training. Prioritize intervals of 3–5 minutes at near-maximal aerobic speed, which have been shown to produce the largest VO₂max gains. Your genetic advantage is maximized when you push your heart's upper limits.

Monitoring cardiac adaptation: Use heart rate variability (HRV)⁹⁹ heart rate variability (HRV)
parasympathetic-mediated recovery indicator to track training adaptation. Endurance athletes typically show higher resting HRV and faster heart rate recovery. When HRV drops outside your weekly baseline, scale back intensity to avoid overtraining—your cardiac system may be reaching its adaptive ceiling despite your genetic edge.

Fuel strategy: The G allele's association with enhanced fatty acid oxidation suggests you may benefit from periodized carbohydrate intake—training fasted or low-carb to upregulate fat-burning enzymes, then fueling with carbs for competition. However, this remains speculative; no studies have directly tested nutrition interventions based on MYBPC3 genotype.

Interactions

The endurance phenotype is polygenic—no single SNP determines performance. rs1052373 works synergistically with other endurance-associated variants including PPARGC1A rs8192678¹⁰¹⁰ PPARGC1A rs8192678
enhances mitochondrial biogenesis and oxidative capacity, ACTN3 rs1815739¹¹¹¹ ACTN3 rs1815739
XX genotype (absence of alpha-actinin-3 fast-twitch protein) associated with endurance over power, and PPARA rs4253778¹²¹² PPARA rs4253778
regulates fatty acid oxidation pathways. If you carry beneficial alleles at multiple loci, the cumulative effect may be substantial.

Conversely, the MYBPC3 gene is also implicated in hypertrophic cardiomyopathy¹³¹³ hypertrophic cardiomyopathy
pathogenic truncating mutations cause HCM, a disease characterized by abnormal thickening of the heart muscle. rs1052373 itself is classified as benign¹⁴¹⁴ classified as benign
all six ClinVar submissions rate it benign for HCM, but it raises an interesting paradox: variants in the same gene can cause both pathological hypertrophy (disease) and adaptive hypertrophy (athlete's heart). The distinction lies in whether the heart thickens symmetrically with preserved function (adaptive) or asymmetrically with impaired relaxation (pathological). If you have a family history of HCM, genetic counseling is warranted regardless of your rs1052373 status.

Growth Differentiation Factor 15 (GDF15) is perhaps the most dramatic hormone you've never heard of. Outside pregnancy its circulating levels sit quietly in the low hundreds of picograms per millilitre. During the first trimester, largely driven by the feto-placental unit, they surge 10- to 100-fold¹¹ 10- to 100-fold
Plasma GDF15 rises from roughly 200–600 pg/mL outside pregnancy to 10,000–100,000 pg/mL in the first trimester; the highest levels are reached around 7–12 weeks. This hormone acts on GFRAL receptors²² GFRAL receptors
Glial cell-derived neurotrophic factor family receptor alpha-like — expressed almost exclusively in the area postrema and nucleus tractus solitarius of the hindbrain; the brain's primary nausea and vomiting control centre in the brainstem, triggering nausea, food aversion, and vomiting. Your rs1054564 genotype determines how much GDF15 you make outside pregnancy — and that baseline sets your sensitivity when the first-trimester surge arrives.

The Mechanism

The rs1054564 variant sits in the 3' untranslated region (3'UTR) of GDF15, a stretch of mRNA that does not encode protein but governs how much of the mRNA is translated. The G allele (carried by ~89% of people globally) maintains the canonical stem-loop secondary structure at this position, allowing hsa-miR-1233-3p³³ hsa-miR-1233-3p
A microRNA that binds the GDF15 3'UTR and suppresses translation; miR-1233-3p is expressed in a range of tissues including adipose, liver, and cardiovascular tissue to bind efficiently and suppress GDF15 translation.

The C allele disrupts the stem-loop structure, reducing miR-1233-3p binding affinity and partially abolishing translational suppression⁴⁴ partially abolishing translational suppression
Reporter assay in HEK293T cells showed significantly higher luciferase activity for the C-allele construct vs G-allele (P=0.034); western blot confirmed reduced endogenous GDF15 protein when miR-1233-3p mimics were transfected into G-allele-bearing cells. The result: C-allele carriers have measurably higher circulating GDF15 at baseline, across all physiological states, throughout their lives.

The Evidence

Metabolic and cardiovascular effects: In a cohort of metabolic disease patients, Guardiola et al. 2024⁵⁵ Guardiola et al. 2024
Guardiola M et al., "The GDF15 3' UTR Polymorphism rs1054564 Is Associated with Diabetes and Subclinical Atherosclerosis." Int J Mol Sci, 2024 found that rs1054564 variant carriers (C-allele) had significantly higher serum GDF15 levels, higher prevalence of diabetes, and higher frequency of subclinical carotid atherosclerosis compared to GG homozygotes, independently of standard confounders. The direction is consistent with the molecular mechanism: more GDF15 → more of the hormone's downstream cardiometabolic stress signalling.

Ho et al. 2012⁶⁶ Ho et al. 2012
Ho JE et al., "Clinical and Genetic Correlates of GDF15 in the Community." Clinical Chemistry, 2012 analysed 2,991 participants in the Framingham Offspring Study and identified rs1054564 as one of two independent cis-expression quantitative trait loci (eQTL) at the GDF15 locus — meaning the variant directly influences how much GDF15 mRNA is made or translated in blood cells, with genome-wide-significant associations (P = 2.74 × 10⁻³²) at the combined locus signal.

Pregnancy nausea and hyperemesis gravidarum: The connection runs in the opposite direction for GG homozygotes. The landmark Fejzo et al. 2024 Nature paper⁷⁷ Fejzo et al. 2024 Nature paper
Fejzo M et al., "GDF15 linked to maternal risk of nausea and vomiting during pregnancy." Nature, 2024; 625(7996):760-767 established that women with lower pre-pregnancy GDF15 levels face higher risk of hyperemesis gravidarum (HG). The proposed mechanism is a desensitisation model: women chronically exposed to higher baseline GDF15 (C-allele carriers, and notably patients with β-thalassemia, who have constitutively elevated GDF15) build tolerance to the hormone's emetic effects, such that the first-trimester surge causes less nausea. Women with lower baseline GDF15 (G-allele homozygotes) have not pre-sensitised their brainstem GFRAL receptors and react more severely to the same fetal GDF15 surge.

Consistent with this model, genetic variants that lower circulating GDF15 were specifically enriched in women with recurrent HG in family studies Fejzo et al. 2018 Nat Commun⁸⁸ Fejzo et al. 2018 Nat Commun
Fejzo MS et al., "Placenta and appetite genes GDF15 and IGFBP7 are associated with hyperemesis gravidarum." Nature Communications, 2018, and a Mendelian randomisation analysis in the 2024 Nature paper further supported that lower baseline GDF15 is causally linked to HG, not merely correlated with it.

Practical Actions

The rs1054564 genotype informs two distinct clinical contexts depending on biological sex and reproductive status:

For women planning pregnancy, the GG genotype identifies a group with lower baseline GDF15 and therefore higher susceptibility to severe pregnancy nausea. This is actionable before conception: pre-pregnancy interventions that raise GDF15 levels (metformin has been shown to increase GDF15, and a 2025 study found pre-pregnancy metformin use was associated with 70–82% reduced HG risk) may be relevant for women with GG and prior HG history, though this remains to be confirmed in prospective trials specifically targeting rs1054564.

For C-allele carriers, the higher baseline GDF15 reduces pregnancy nausea susceptibility but introduces a different consideration: chronically elevated GDF15 is a biomarker of metabolic stress, and the variant independently increases diabetes and subclinical atherosclerosis risk. Fasting glucose and carotid ultrasound are the specific screening tools that correspond to this genotype's risk profile.

Interactions

rs45543339 and rs1054221 (GDF15, same gene): These are the two common GDF15 haplotype-tagging variants identified in the Fejzo 2024 GWAS of hyperemesis gravidarum. They likely tag partially overlapping haplotypes with rs1054564. The combined effect of carrying low-expression variants at multiple GDF15 regulatory positions has not been formally analysed but would be expected to compound the reduction in baseline GDF15.

rs888663 (GDF15 promoter): rs888663 is the primary cis-eQTL signal at the GDF15 locus identified in the Ho 2012 Framingham study — a stronger signal than rs1054564, which is a secondary independent signal at the same locus. The two variants likely have independent but additive effects on GDF15 expression through different regulatory mechanisms (promoter activity vs 3'UTR translation).

GDF15, once called macrophage inhibitory cytokine-1 or MIC-1¹¹ macrophage inhibitory cytokine-1 or MIC-1
GDF15 was independently discovered several times and given different names: MIC-1, NAG-1, PLAB, and PDF. All refer to the same gene on chromosome 19, is one of the most versatile stress signals in human biology. Produced at low levels by most organs under normal conditions, it surges in response to cellular injury, metabolic overload, inflammation, pregnancy, and cancer. Once released into the bloodstream, it crosses into the brainstem where it binds the GFRAL receptor²² GFRAL receptor
Glial cell line-derived neurotrophic factor family receptor alpha-like — expressed almost exclusively in the area postrema and nucleus tractus solitarii, the brainstem regions that coordinate nausea and appetite suppression, recruiting the co-receptor RET to trigger appetite suppression, nausea, and reduced food intake. It also serves as a potent biomarker: elevated circulating GDF15 consistently predicts all-cause mortality, cardiovascular events, and metabolic dysfunction. The rs1059369 (S48T) variant sits in the coding region of GDF15, and its genetic context — the haplotype it tags — modulates how much of this stress signal your body produces.

The Mechanism

The rs1059369 variant converts serine to threonine at position 48 of the GDF15 preproprotein (NM_004864.4:c.142T>A, p.Ser48Thr). Position 48 falls within the signal peptide and propeptide region³³ signal peptide and propeptide region
GDF15 is synthesized as a 308-amino-acid preproprotein. The signal peptide (~28 aa) directs the protein to the secretory pathway; the propeptide (~167 aa) is cleaved by furin-like proteases before the mature 112-amino-acid dimer is secreted — the portion of the protein that is cleaved before secretion. The serine-to-threonine substitution is chemically conservative (both hydroxyl-bearing), and the S48T change alone is not predicted to substantially alter the mature secreted protein's structure or receptor binding.

The variant's primary role is as a haplotype tag⁴⁴ haplotype tag
A SNP that reliably tracks another nearby variant through linkage disequilibrium — the non-random co-inheritance of nearby genetic variants. A three-SNP study of the GDF15 locus in hypertensive patients found that rs1059369 tags a haplotype anchored by the -3148C>G promoter variant (rs4808793), which increases GDF15 transcriptional activity 1.45-fold at baseline and 1.73-fold under adrenergic stimulation. The A allele at rs1059369 co-segregates with the G allele at rs4808793 in a haplotype associated with higher plasma GDF15 and more favorable cardiac remodeling. The functional driver appears to be the promoter variant; rs1059369 is the coding-region marker that travels with it.

The Evidence

Wang et al. (2009)⁵⁵ Wang et al. (2009)
Wang X et al. The haplotype of the growth-differentiation factor 15 gene is associated with left ventricular hypertrophy in human essential hypertension. Clin Sci (Lond), 2009 genotyped 1,527 hypertensive patients for three GDF15 variants including rs1059369 (+157A>T). The haplotype carrying the A allele was associated with a 25% lower odds of left ventricular hypertrophy (OR=0.75, 95% CI 0.63-0.89, P=0.0009), and carriers showed significantly higher circulating GDF15 levels (P=0.04). This suggests that the A-allele haplotype upregulates GDF15 expression, and that moderately elevated GDF15 is cardioprotective in the hypertensive context — consistent with GDF15's known role in anti-hypertrophic signaling in the heart.

A large integrated analysis by Lemmelä et al. (2022)⁶⁶ Lemmelä et al. (2022)
Lemmelä S et al. Integrated analyses of growth differentiation factor-15 concentration and cardiometabolic diseases in humans. eLife, 2022 across 14,099 individuals found that circulating GDF15 predicts all-cause mortality, cardiometabolic disease, respiratory illness, and psychiatric disorders, but Mendelian randomization did not support elevated GDF15 as a causal driver of cardiometabolic disease. Instead, GDF15 rises in response to metabolic stress (including obesity, which causally elevates GDF15, IVW pFDR = 0.0040). The picture is that of a biomarker reading, not a culprit — though the GFRAL-mediated appetite suppression pathway is real and pharmacologically targetable.

In pregnancy, where GDF15 rises dramatically and drives nausea via the GFRAL receptor, Pereira et al. (2026)⁷⁷ Pereira et al. (2026)
Pereira DA et al. Functional characterization of the GWAS lead SNP rs888663 and effects of GDF15 SNPs on GDF15 levels in gestational hypertension and preeclampsia. Mol Biol Rep, 2026 found that TT genotype carriers with preeclampsia or gestational hypertension had lower GDF15 levels than healthy pregnant TT carriers (P<0.05), linking rs1059369 genotype to gestational GDF15 regulation in pathological pregnancies.

Practical Actions

For TT individuals (the common genotype), no specific GDF15-related intervention is needed. The TT genotype produces typical GDF15 stress signaling. For AT and AA carriers, the A allele haplotype is associated with higher circulating GDF15 at baseline, which in the context of metabolic stress (obesity, hypertension, inflammatory conditions) could influence appetite regulation, nausea sensitivity, and cardiac remodeling. Notably, GDF15 is one of the mechanisms by which metformin reduces appetite and body weight — carriers with higher GDF15 may have a more pronounced response to this mechanism.

Because GDF15 is fundamentally a stress-response biomarker, the most actionable insight is using it as a monitoring tool: elevated circulating GDF15 (above ~600 pg/mL in non-pregnant adults) signals metabolic or inflammatory stress and warrants investigation of its cause.

Interactions

rs1059369 is in linkage disequilibrium with rs4808793 (GDF15 promoter) and rs1058587 (H202D, the major GWAS variant for circulating GDF15 levels). The A allele at rs1059369 co-travels with the protective haplotype identified by Wang et al. The most important related variant is rs1058587 (H202D): this variant's G allele is present in approximately 21% of Europeans and substantially affects assay-measured GDF15 levels due to epitope interference — a nuance relevant to interpreting commercial GDF15 blood tests rather than biology per se. For individuals tracking GDF15 as a longevity biomarker, the rs1058587 H202D status is more informative than rs1059369.

The CFH Y402H variant (also called Tyr402His) is the single most important genetic contributor to age-related macular degeneration¹¹ age-related macular degeneration
AMD is the leading cause of irreversible blindness in people over 50 in developed countries, a progressive disease that destroys the sharp central vision needed for reading and driving. Complement Factor H is a negative regulator of the alternative complement pathway, acting as a brake on inflammatory responses. The Y402H substitution — replacing tyrosine with histidine at position 402 — sits within a critical binding domain where CFH interacts with C-reactive protein and glycosaminoglycans on cell surfaces, particularly in the retina.

The Mechanism

The histidine variant at position 402 reduces CFH's ability to bind to heparan sulfate and other glycosaminoglycans²² heparan sulfate and other glycosaminoglycans
These molecules coat the surface of retinal pigment epithelium cells and Bruch's membrane, where CFH normally regulates complement activation in Bruch's membrane and on retinal pigment epithelium cells. This impaired binding means CFH-402H cannot effectively suppress complement activation at these sites, leading to chronic low-grade inflammation in the macula. The 402H variant also binds less effectively to malondialdehyde³³ malondialdehyde
MDA is a lipid peroxidation product that accumulates with aging and oxidative stress, a common lipid peroxidation product that accumulates in drusen — the hallmark yellow deposits beneath the retina in AMD. The result is uncontrolled complement-mediated damage to photoreceptors and retinal pigment epithelium, culminating in geographic atrophy (dry AMD) or choroidal neovascularization (wet AMD).

The Evidence

The CFH Y402H association with AMD represents one of the most robust findings in complex disease genetics. The Rotterdam Study⁴⁴ The Rotterdam Study
5,681 participants with up to 10 years of follow-up found that CC homozygotes have an 11-fold increased risk of late AMD compared to TT individuals, with cumulative risks of vision-threatening disease by age 95 reaching 48.3% for CC, 42.6% for TC, and 21.9% for TT. Population-attributable risk was calculated at 54%, meaning more than half of AMD cases in populations of European descent can be traced to this variant. A systematic meta-analysis⁵⁵ A systematic meta-analysis
Combined data from 8 studies confirmed a multiplicative model where each C allele increases AMD odds by approximately 2.5-fold, with highly consistent effects across Caucasian populations.

The variant's clinical significance extends to treatment response. A meta-analysis of anti-VEGF therapy⁶⁶ A meta-analysis of anti-VEGF therapy
Included 1,510 patients with neovascular AMD for wet AMD found OR 1.68 (95% CI 1.09-2.60) for CC vs TT treatment response; multiple subsequent analyses show CC patients require more frequent injections and achieve more variable outcomes. Patients with CC genotype⁷⁷ Patients with CC genotype
Analysis from multiple treatment cohorts required a mean of 10.8 intravitreal injections over 12 months versus 7.2 for TC/TT genotypes. The strength of association varies substantially by ethnicity: highly significant in Europeans (C allele frequency ~36%), weaker in East Asian populations⁸⁸ East Asian populations
C allele frequency ~7% in Japanese and Korean cohorts where other variants like CFH I62V (rs800292) play a larger role.

Practical Implications

If you carry one or two C alleles, your AMD risk is meaningfully elevated, but AMD is not inevitable — onset typically occurs after age 60, and environmental factors modulate risk substantially. The most critical modifiable factor is smoking: smokers with CC genotype⁹⁹ smokers with CC genotype
Rotterdam Study data have a 34-fold increased risk compared to TT non-smokers, versus 11-fold for CC non-smokers. Quitting smoking at any age reduces risk, and the benefit applies regardless of genotype.

For CC homozygotes and high-risk TC heterozygotes, annual dilated eye exams starting at age 50 are prudent, with more frequent monitoring (every 6 months) if early drusen or pigmentary changes appear. Self-monitoring with an Amsler grid¹⁰¹⁰ Self-monitoring with an Amsler grid
A simple checkerboard pattern test that can detect early distortions in central vision at home can catch sudden changes indicating conversion to wet AMD, where urgent treatment can preserve vision. AREDS2 supplementation (vitamin C, vitamin E, zinc, copper, lutein, and zeaxanthin) reduces progression risk by approximately 25% in individuals with intermediate AMD, though evidence for benefit in those without existing disease is weaker.

Dietary patterns may play a role: foods rich in lutein and zeaxanthin — particularly leafy greens and colorful vegetables — as well as fatty fish rich in omega-3s, have been studied in the context of AMD risk and CFH genotype¹¹¹¹ the context of AMD risk and CFH genotype, though evidence for a protective effect specifically in high-risk CFH genotypes remains preliminary. Blue light exposure from screens is often cited as a concern, but evidence is weak; far more important is ultraviolet protection¹²¹² ultraviolet protection
Chronic UV exposure contributes to oxidative damage in the retina through high-quality sunglasses that block UV rays.

If you develop wet AMD, a meta-analysis suggests CC homozygotes may respond better to anti-VEGF therapy than other genotypes, though individual responses vary and close monitoring remains essential. Emerging complement inhibitors targeting the alternative pathway are in late-stage trials and may offer genotype-specific benefits for CFH variant carriers in the coming years.

Interactions

CFH Y402H interacts multiplicatively with variants in ARMS2 (rs10490924 A69S), the second major AMD risk locus. Individuals with high-risk alleles at both loci¹³¹³ Individuals with high-risk alleles at both loci
Both CFH CC and ARMS2 TT genotypes — CFH CC plus ARMS2 TT (risk allele) — have synergistically elevated AMD risk exceeding the product of individual effects, suggesting convergent pathways in complement activation and extracellular matrix regulation. Interestingly, RMD subtype of AMD¹⁴¹⁴ RMD subtype of AMD
Reticular macular disease, characterized by yellow interlacing networks in the macula shows an inverse association with CFH 402H but positive association with ARMS2 69S, hinting at distinct pathogenic mechanisms within the AMD spectrum.

The gene-environment interaction with smoking is particularly striking: the combination of CFH risk alleles and smoking¹⁵¹⁵ the combination of CFH risk alleles and smoking
Data from multiple cohorts including Rotterdam Study amplifies risk far beyond additive expectations, likely because cigarette smoke components directly activate the complement cascade and generate oxidative stress that overwhelms the already-impaired regulatory capacity of CFH-402H. Other CFH variants including rs1410996 and rs800292 show complex haplotype effects and may refine risk prediction when considered jointly with Y402H.

Compound implications involving CFH Y402H and ARMS2 rs10490924 should be considered when both variants are present, as the combined risk profile may warrant earlier screening and more aggressive preventive measures than either variant alone would suggest.